Cytosorbents Corporation（Cytosorbents）宣布，其Cytosorb设备在冠状动脉旁路移植术（CABG）患者中的使用，与严重出血事件的相对减少37%存在关联。这一数据凸显了该技术在心脏外科手术中可能带来的临床获益，尤其是在改善患者预后方面。Cytosorbents的这项发现，为Cytosorb在围手术期管理中的应用提供了新的证据支持，有望在未来进一步推动其在临床实践中的广泛采用。
Cytosorbents Corporation（Cytosorbents）宣布，其Cytosorb设备在冠状动脉旁路移植术（CABG）患者中的使用，与严重出血事件的相对减少37%存在关联。这一数据凸显了该技术在心脏外科手术中可能带来的临床获益，尤其是在改善患者预后方面。Cytosorbents的这项发现，为Cytosorb在围手术期管理中的应用提供了新的证据支持，有望在未来进一步推动其在临床实践中的广泛采用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.